Skip to search formSkip to main contentSkip to account menu

tipifarnib

Known as: (+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 2 (1H))-quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-,(+)- 
A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (2)

Antineoplastic AgentsQuinolones

Narrower (2)

R115777Zarnestra

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Simultaneous Inhibition of the Raf/MEK/ERK and PI3K/Atk/mTOR Pathways has Significant Synergistic Effects on Proliferation and Migration in C6 Glioma Cancer Cells
The effect of combining Raf/ERK pathway inhibitors with PI3K/mTOR pathway inhibitors in C6 glioma brain cancer cells was studied… 
2011
2011
L'associazione Tipifarnib-Bortezomib nel trattamento delle leucemie acute mieloidi: risultati di uno studio multicentrico di fase I/II e validazione di un profilo genico predittivo di risposta
Background. Outcome of elderly acute myeloid leukemia (AML) patients is dismal. Targeted-therapies might improve current results… 
2010
2010
A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas
Abstract 287 Purpose: Farnesyltransferases are key cellular enzymes involved in the prenylation of proteins. Prenylated proteins… 
2007
2007
Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205
1037 Background: Tipifarnib and fulvestrant both have single agent activity in hormone receptor-positive (HR+) metastatic breast… 
2007
2007
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT).
Budesonide (an anti-inflammatory glucocorticoid), R115777 (a farnesyl transferase inhibitor, Zarnestra, Tipifarnib) or… 
2007
2007
Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
14014 Background: Tipifarnib (T) is a farnesyltransferase inhibitor with clinical activity in MDS and AML. LDAC has utility in… 
2007
2007
Running head: TIPIFARNIB IN REFRACTORY OR RELAPSED AML
From the Service d’Hématologie, Hôtel Dieu, Nantes, France; H. Lee Moffitt Cancer Center & Research Institute, University of… 
2005
2005
A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors
3000 Background: Preclinical data indicates that the EGFR tyrosine kinase inhibitor erlotinib demonstrates greater than additive… 
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
2002
2002
Gateways to Clinical Trials: July-August 2002
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…